Page 1060 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

References 7

and amikacin in the empirical treatment of febrile, neutropenic 196. Chandrasekar PH, Arnow PM. Cefepime versus ceftazidime as
children with cancer. New Engl J Med. 1988;319:1053-1058. empiric therapy for fever in neutropenic patients with cancer.
182. Fanci R, Paci C, Leoni F, Casini C, Longo G. Ticarcillin- Ann Pharmacother. 2000;34(9):989-995.
clavulanic acid plus amikacin versus ceftazidime plus amikacin 197. Chuang YY, Hung IJ, Yang CP, Jaing TH, Lin TY, Huang YC.
in the empirical treatment of fever in acute leukemia: a prospec- Cefepime versus ceftazidime as empiric monotherapy for fever
tive randomized trial. J Chemother. 2003;15(3):253-259. and neutropenia in children with cancer. Pediatr Infect Dis J.
183. Fleming DR, Ziegler C, Baize T, Mudd L, Goldsmith GH, Herzig 2002;21(3):203-209.
RH. Cefepime versus ticarcillin and clavulanate potassium and 198. Meropenem Study Group of Leuven L, Nijmegen. Equivalent
aztreonam for febrile neutropenia therapy in high-dose chemo- efficacies of meropenem and ceftazidime as empirical mono-
therapy patients. Am J Clin Oncol. 2003;26(3):285-288. therapy of febrile neutropenic patients. The Meropenem
184. Petrilli AS, Cypriano M, Dantas LS, et al. Evaluation of Study Group of Leuven, London and Nijmegen. J Antimicrob
ticarcillin/clavulanic acid versus ceftriaxone plus amikacin for Chemother. 1995;36(1):185-200.
fever and neutropenia in pediatric patients with leukemia and 199. Vandercam B, Gerain J, Humblet Y, et al. Meropenem versus
lymphoma. Braz J Infect Dis. 2003;7(2):111-120. ceftazidime as empirical monotherapy for febrile neutropenic
185. Innes HE, Smith DB, O'Reilly SM, Clark PI, Kelly V, Marshall E. cancer patients. Ann Hematol. 2000;79(3):152-157.
Oral antibiotics with early hospital discharge compared with in- 200. de la Camara R, Figuera A, Sureda A, et al. Meropenem versus
patient intravenous antibiotics for low-risk febrile neutropenia ceftazidime plus amikacin in the treatment of febrile episodes
in patients with cancer: a prospective randomised controlled in neutropenic patients: a randomized study. Haematologica.
single centre study. Br J Cancer. 2003;89(1):43-49. 1997;82(6):668-675.
186. Yu LC, Shaneyfelt T, Warrier R, Ode D. The efficacy of ticarcil- 201. Lindblad R, Rodjer S, Adreasson B, et al. Empiric monother-
lin-clavulanate and gentamicin as empiric treatment for febrile apy for febrile neutropenia—a randomized study comparing
neutropenic pediatric patients with cancer. Pediatr Hematol meropenem with ceftazidime. Scand J Infect Dis. 1998;30(3):
Oncol. 1994;11(2):181-187. 237-243.
187. Marie JP, Vekhoff A, Cony-Makhoul P, et al. Piperacillin/ 202. Behre G, Link H, Maschmeyer G, et al. Meropenem monother-
tazobactam combination + amikacin versus ceftazidime + apy versus combination therapy with ceftazidime and amikacin
amikacin in patients with neutropenia and fever: an open for empirical treatment of febrile neutropenic patients. Ann
multicenter Study. Group d'etudes dea Aplasies Febriles. Presse Hematol. 1998;76(2):73-80.
Medicale. 1995;24(8):397-401.
188. Marie JP, Marjanovic Z, Vekhoff A, et al. Piperacillin/ tazobactam 203. Akova M, Akan H, Korten V, et al. Comparison of meropenem
plus tobramycin versus ceftazidime plus tobramycin as empiric with amikacin plus ceftazidime in the empirical treatment of
therapy for fever in severely neutropenic patients. Support Care febrile neutropenia: a prospective randomised multicentre
Cancer. 1999;7(2):89-94. trial in patients without previous prophylactic antibiotics.
Meropenem Study Group of Turkey. Int J Antimicrob Agents.
189. Sage R, Hann I, Prentice HG, et al. A randomized trial of empir- 1999;13(1):15-19.
ical antibiotic therapy with one of four beta-lactam antibiotics
in combination with netilmicin in febrile neutropenic patients. 204. Feld R, De Pauw B, Berman S, Keating A, Ho W. Meropenem
J Antimicrob Chemother. 1988;22(2):237-247. versus ceftazidime in the treatment of cancer patients with
febrile neutropenia: a randomized, double-blind trial. J Clin
190. Bolton-Maggs PH, van Saene HK, McDowell HP, Martin J. Oncol. 2000;18(21):3690-3698.
Clinical evaluation of ticarcillin, with clavulanic acid, and
gentamicin in the treatment of febrile episodes in neutropenic 205. Freifeld AG, Baden LR, Brown AE, et al. Fever and neutropenia.
children. J Antimicrob Chemother. 1991;27(5):669-676. J National Comprehensive Cancer Network. 2004;2(5):390-432.
191. Schaison G, Reinert P, Leverger G, Leaute JB. Timentin (ticarcil- 206. Freifeld A. Guidelines for antimicrobials in neutropenic cancer
lin and clavulanic acid) in combination with aminoglycosides patients. Paper presented at: 45th Annual Meeting of the
in the treatment of febrile episodes in neutropenic children. Infectious Diseases Society of America; October 4-7, 2007; San
J Antimicrob Chemother. 1986;17(suppl C):177-181. Diego, California.
192. Laverdiäre M, Bow EJ, Rotstein C, Ioannou S, Carr D, 207. Garcia-Rodriguez JA, Gobernado M, Gomis M, et al. Clinical
Moghaddam N. Antimicrobial regimens prescribed by guide for the evaluation and treatment of patients with neutro-
Canadian physicians for chemotherapy-induced febrile neutro- penia and fever. Rev Esp Quimioter. 2001;14(1):75-83.
penic episodes. Can J Infect Dis. 1999;10(5):353-357. 208. Paul M, Soares-Weiser K, Leibovici L. Beta lactam monotherapy
193. Cordonnier C, Herbrecht R, Pico JL, et al. Cefepime/amikacin versus beta lactam-aminoglycoside combination therapy for
versus ceftazidime/amikacin as empirical therapy for febrile epi- fever with neutropenia: systematic review and meta-analysis.
sodes in neutropenic patients: a comparative study. The French BMJ. 2003;326(7399):1111-1120.
Cefepime Study Group. Clin Infect Dis. 1996;24(1):41-51. 209. Kumar A, Safdar N, Kethireddy S, Chateau D. A survival benefit
194. Cornely OA, Bethe U, Seifert H, et al. A randomized monocentric of combination antibiotic therapy for serious infections associ-
trial in febrile neutropenic patients: ceftriaxone and gentamicin ated with sepsis and septic shock is contingent only on the risk
vs cefepime and gentamicin. Ann Hematol. 2002;81(1):37-43. of death: a meta-analytic/meta-regression study. Crit Care Med.
195. Erman M, Akova M, Akan H, et al. Comparison of cefepime August 2010;38(8):1651-1664.
and ceftazidime in combination with amikacin in the empiri- 210. Kumar A, Zarychanski R, Light B, et al. Early combination
cal treatment of high-risk patients with febrile neutropenia: a antibiotic therapy yields improved survival compared with
prospective, randomized, multicenter study. Scand J Infect Dis. monotherapy in septic shock: a propensity-matched analysis.
2001;33(11):827-831. Crit Care Med. September 2010;38(9):1773-1785.

Section05-O-ref.indd 7 1/20/2015 4:51:19 PM